Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra W Cowan-Jacob

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Pharmacology & Therapeutics|August 23, 2002
Protein kinases as targets for anticancer agents: from inhibitors to useful drugsDoriano Fabbro, Stephan Ruetz, Elisabeth Buchdunger, et al.
Journal of Medicinal Chemistry|October 16, 2009
Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypesJürgen Wagner, Peter von Matt, Richard Sedrani, et al.
Biochimica Et Biophysica Acta|February 16, 2010
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding siteDoriano Fabbro, Paul W Manley, Wolfgang Jahnke, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2007
Novel scaffold for cathepsin K inhibitorsNaoki Teno, Takahiro Miyake, Takeru Ehara, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2017
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitorsAaron Smith, Zhi-Jie Ni, Daniel Poon, et al.
Cancer Cell|February 16, 2005
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblEllen Weisberg, Paul W Manley, Werner Breitenstein, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Pharmacology & Therapeutics|August 23, 2002
Protein kinases as targets for anticancer agents: from inhibitors to useful drugsDoriano Fabbro, Stephan Ruetz, Elisabeth Buchdunger, et al.
Journal of Medicinal Chemistry|October 16, 2009
Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypesJürgen Wagner, Peter von Matt, Richard Sedrani, et al.
Biochimica Et Biophysica Acta|February 16, 2010
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding siteDoriano Fabbro, Paul W Manley, Wolfgang Jahnke, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2007
Novel scaffold for cathepsin K inhibitorsNaoki Teno, Takahiro Miyake, Takeru Ehara, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2017
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitorsAaron Smith, Zhi-Jie Ni, Daniel Poon, et al.
Cancer Cell|February 16, 2005
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblEllen Weisberg, Paul W Manley, Werner Breitenstein, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Pageof 4